7.52

1.48% 0.11

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $7.52, with a volume of 1.60M. It is up +1.48% in the last 24 hours and up +5.92% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Previous Close:

$7.41

Open:

$7.44

24h Volume:

1.60M

Relative Volume:

0.64

Market Cap:

$1.25B

Revenue:

$246.03M

Net Income/Loss:

$-32.00M

P/E Ratio:

-35.39

EPS:

-0.2125

Net Cash Flow:

$-16.78M

1W Performance:

-5.17%

1M Performance:

+5.92%

6M Performance:

+42.97%

1Y Performance:

+133.54%

1-Day Range:

$7.38

$7.62

1-Week Range:

$7.365

$7.97

52-Week Range:

$3.15

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

394

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	7.52	1.23B	246.03M	-32.00M	-16.78M	-0.2125
VRTX Vertex Pharmaceuticals Inc	441.36	111.36B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	733.04	77.98B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	800.01	50.33B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.27	47.46B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	338.19	37.43B	4.98B	69.59M	525.67M	0.5197

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Aug-12-25	Resumed	H.C. Wainwright	Buy
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Jan 16, 2026

Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative? - simplywall.st

Jan 16, 2026

Jan 15, 2026

How Investors Are Reacting To Xeris Biopharma (XERS) Raising 2025 Revenue Outlook And Recorlev Momentum - Sahm

Jan 15, 2026

Jan 14, 2026

Technical Analysis: What are Xeris Biopharma Holdings Incs technical support levels2025 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn

Jan 14, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 14, 2026

Jan 10, 2026

Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? - Yahoo Finance

Jan 10, 2026

Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns - Yahoo Finance

Jan 10, 2026

Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates - Sahm

Jan 10, 2026

Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents - Yahoo Finance

Jan 10, 2026

XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Pric - GuruFocus

Jan 10, 2026

Jan 09, 2026

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock - MarketBeat

Jan 09, 2026

Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright - MarketBeat

Jan 09, 2026

Published on: 2026-01-13 01:49:04 - ulpravda.ru

Jan 09, 2026

Jan 08, 2026

Will Xeris Biopharma Holdings Inc. stock outperform tech sector in 20252025 EndofYear Setup & Weekly High Potential Stock Alerts - Улправда

Jan 08, 2026

Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus

Jan 08, 2026

Breakout Move: Is Xeris Biopharma Holdings Inc. stock a smart buy before Fed meetingJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда

Jan 08, 2026

How Xeris Biopharma Holdings Inc. stock benefits from strong dollarJuly 2025 Update & AI Powered Buy and Sell Recommendations - Улправда

Jan 08, 2026

Is Xeris Biopharma Holdings Inc. stock positioned well for digital economyBreakout Watch & Smart Allocation Stock Reports - Улправда

Jan 08, 2026

Xeris Biopharma expects full-year 2025 revenue above estimates - MSN

Jan 08, 2026

Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's Why - MarketBeat

Jan 08, 2026

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - BioSpace

Jan 08, 2026

Xeris Biopharma Holdings, Inc. Updates Earnings Guidance for the Full-Year 2025 - marketscreener.com

Jan 08, 2026

A biotech treating 700 patients is on track for a record revenue year - Stock Titan

Jan 08, 2026

Jan 07, 2026

Xeris Biopharma director Shannon sells $176k in shares By Investing.com - Investing.com Nigeria

Jan 07, 2026

Jan 06, 2026

Xeris Biopharma director Shannon sells $176k in shares - Investing.com

Jan 06, 2026

Xeris Biopharma (NASDAQ:XERS) Insider Sells $176,341.56 in Stock - MarketBeat

Jan 06, 2026

Jan 05, 2026

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat

Jan 05, 2026